David Stephen Shulman, M.D.
Instructor in Pediatrics
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
450 Brookline Ave
Boston MA 02215
|Harvard Medical School, Boston, MA||MD||06/2013||Medicine|
|Boston Combined Residency in Pediatrics, Boston, MA||06/2014||Internship|
|Boston Combined Residency in Pediatrics, Boston, MA||06/2016||Residency|
|Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA||06/2019||Fellowship (Pediatric Hematology/Oncology)|
Available: 03/01/21, Expires: 09/30/21
The development of CNS metastases is a devastating event for patients with relapsed sarcoma. In our practice, we have anecdotally noted increased numbers of patients who have developed CNS metastatic disease in recent years. Our hypothesis is that with the increasing use of targeted therapies for patients with relapsed sarcomas, the CNS has become a sanctuary site of relapse and the incidence of CNS relapse has increased. We aim to leverage an existing database we have developed that includes patients with solid tumors who have received targeted therapies in attempt to better understand the development of CNS metastases in patients with sarcoma.
The proposed project will fall under the experimental therapeutics program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. We have a research program focused on novel therapies for children with relapsed cancer. Our program carries out a series of ancillary clinical research projects to better understand the landscape of novel targeted therapies as well as the clinical behavior of children with relapsed solid tumors. The proposed project would be expected to be driven by a student under the mentorship of Dr. Shulman. The student should expect to participate in completion of the project design, curate existing data and collect new data, analyze the data under the mentorship of Dr. Shulman, and draft a first author manuscript. This project will involve training in clinical research in pediatric oncology, study design, manuscript preparation, and could involve shadowing in the care of children with advanced solid tumors.
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
to make corrections and additions.
Oct 1, 2020 - Sep 30, 2022
Harvard Catalyst / NIH. - KL2/CMeRIT
Evaluation of precision biomarkers and targeted therapies in patients with Ewing sarcoma
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.